Navigation Links
Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
Date:3/3/2008

SEATTLE, March 3 /PRNewswire-FirstCall/-- Dendreon Corporation (Nasdaq: DNDN) announced the publication of a manuscript titled, "CD54 is a surrogate marker of antigen presenting cell activation" in Cancer Immunology, Immunotherapy.

The manuscript describes and supports the use of CD54 as a surrogate marker of antigen presenting cell activation (APC) activation and validates its utility as a potency measure of PROVENGE(R) (sipuleucel-T). In particular, it describes how Dendreon researchers used CD54 and the upregulation of its expression on antigen presenting cells (APC) as a means by which human APC activation could be assessed and most importantly, how such measurements could be used to determine the potency of PROVENGE before its administration to patients with prostate cancer. The assessment of product potency is a key release measure required by the U.S. Food and Drug Administration (FDA).

The upregulation of CD54 has been used as part of the potency assay for PROVENGE since the initiation of the PROVENGE clinical development program. Data correlating CD54 upregulation to overall survival in patients from two Phase 3 trials, D9901 and D9902A have been presented at recent scientific meetings and at the FDA Cell Tissue and Gene Therapy Advisory Committee Meeting on March 29, 2007.

About Active Cellular Immunotherapy with PROVENGE

PROVENGE may represent the first product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. In clinical studies, patients typically received three doses of PROVENGE over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
9. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
10. Consortium publishes Phase II map of human genetic variation
11. The Lancet Publishes Vasogens ACCLAIM Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Research and Markets has ... Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on ... The report provides a basic overview ... industry chain structure. The N-acetylcysteine market analysis is ...
(Date:9/18/2014)... 2014 Research and Markets has ... (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends ... The global companion diagnostics market is ... 2014 to 2019. Factors such as rising need for ... diagnostics by the pharmaceutical industry, support from regulatory authorities, ...
(Date:9/18/2014)... ST. LOUIS , Sept. 18, 2014  U.S. ... portfolio by signing an exclusive license for technology developed ... to control gene expression in plants, including for applications ... species. The technology was developed under ... science officer at Kultevat and former president of the ...
(Date:9/18/2014)... 2014  Neogen Corporation (Nasdaq: NEOG ) ... agreement with Merck Animal Health to market Neogen,s Igenity ... Igenity Dairy Heifer Program consists of genomic tests that ... potential of replacement dairy heifers. The genomic tests can ... is an excellent tool in the decision-making process for ...
Breaking Biology Technology:Global N-acetylcysteine Industry Report 2014 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Kultevat obtains license of gene switch technology 2Merck Animal Health to market Neogen's dairy genomic program 2
... LABS, Inc., the recognized leader in microbiology, infectious ... the transplant and biomedical sciences communities, today announced ... President of Strategic Development following two years with ... LABS, Inc. client base significantly. In ...
... announced the sale of its leading Sustenex® ... dietary supplements to Schiff Nutrition International, Inc. ... royalties on Schiff products containing GanedenBC30 ™.  The ... probiotic technology, GanedenBC30™, in the over-the-counter (OTC) and dietary ...
... 2011 To aid the fight of the deadly ... and their collaborators at the University Medical Centre Hamburg-Eppendorf ... upon the sequencing data previously released and submitted to ... the first genomes assembled using the latest ion semiconductor ...
Cached Biology Technology:LABS, Inc. Promotes Chad Ronholdt to VP of Strategic Development 2Ganeden Biotech Completes $40 Million Sale of Sustenex® and Digestive Advantage® Probiotic Brands 2Ganeden Biotech Completes $40 Million Sale of Sustenex® and Digestive Advantage® Probiotic Brands 3Further Analysis on Improved Genome Assembly Indicates the Outbreak E. coli has Complex Genetics With Resistance to at Least Eight Antibiotics 2Further Analysis on Improved Genome Assembly Indicates the Outbreak E. coli has Complex Genetics With Resistance to at Least Eight Antibiotics 3
(Date:9/18/2014)... the fish world, are the ideal animal in which ... moved from the ocean into tens of thousands of ... changing their skeleton to adapt to the new environment. ... sticklebacks now have turned up one of the genes ... change in that gene,s regulation in a freshwater population ...
(Date:9/18/2014)... has found clownfish larvae can swim up to 400 kilometres ... to cope with environmental change. , Clownfish spend their entire ... as babies they must wander the open ocean, says study ... for Coral Reef Studies (Coral CoE) at James Cook University. ... but now we,ve been given a rare glimpse into how ...
(Date:9/17/2014)... to reproductive technologies, the justice and well-being of ... to identify key issues, articulate their values and ... most defensible ways forward. But what are the ... The Hastings Center and the Presidential Commission for ... to publish a series of essays to highlight ...
Breaking Biology News(10 mins):Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Nemo's epic journey to find a new home 2Why bioethics literacy matters 2Why bioethics literacy matters 3
... that as some populations of an organism evolve a ... segment of the lifespan that contributes to "fitness" ?the ... the next generation. , Focusing on guppies, small fresh-water ... that guppies living in environments with a large number ...
... teeth and jawbones of two new species of tiny monkey-like ... from ancient sediments in the Egyptian desert, researchers have reported. ... common ancestor of living anthropoids -- including monkeys, apes and ... already begun branching into many species by that time. Also, ...
... Institute of Allergy and Infectious Diseases (NIAID), part ... how a promising drug candidate attacks the bacterium ... in Proceedings of the National Academy of Sciences, ... candidate, PA-824, which targets Mycobacterium tuberculosis (M. tb). ...
Cached Biology News:Fish evolve a longer lifespan by evolving a longer reproductive period, researchers find 2Ancient anthropoid origins discovered in Africa 2Ancient anthropoid origins discovered in Africa 3NIAID researchers show how promising TB drug works 2NIAID researchers show how promising TB drug works 3
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... subcloning of gene in baculoviral expression ... and plaque purification of ten clones, ... for one clone, protein expression and ... culture. Expected yield and timeline: 1-4 ...
... Custom Synthesis Service provides you ... to knockdown any gene. We ... base pairs with terminal dT ... other lengths of your choice. ...
EDG-1 Western blot control Source: Cell Lysate Application: Western Blotting Control...
Biology Products: